168 patents currently held
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Alexion Pharmaceuticals, Inc. portfolio ends in Jan 2027, and more of its terms end in 2031 (21) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
41
Ending by 2030
Jan 2027
Next term end
101
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2035 · High confidence
Also notable
Ends Dec 2032 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends Jul 2029 · High confidence
Also notable
Ends Dec 2031 · High confidence
Also notable
Ends no later than Mar 2027 · Medium confidence
Also notable
Ends Nov 2027 · High confidence
Also notable
Ends Oct 2038 · High confidence
ANTI-C5 Antibodies Having Improved Pharmacokinetics
US 9,079,949
Cited by 80 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Methods and Compositions for Treating Complement-Associated Disorders
US 9,447,176
Cited by 92 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Antidotes for Factor Xa Inhibitors and Methods of Using the Same
US 8,153,590
Cited by 79 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2034.
Inhibitors of Protein Kinases
US 8,138,339
The most cited patent in this portfolio, cited by 109 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2029.
ANTI-C5A Antibodies
US 9,011,852
Cited by 57 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
US 9,725,504
Cited by 33 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Antibodies to OX-2/CD200 and Uses Thereof
US 8,075,884
Cited by 56 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
High Concentration ANTI-C5 Antibody Formulations
US 11,365,241
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 14 to 21, 2027 · next Jan 14
- 4 fees due Feb 1 to 18, 2027 · next Feb 1
- 4 fees due Mar 10 to 22, 2027 · next Mar 10
- 3 fees due Apr 22 to 30, 2027 · next Apr 22
- 3 fees due May 7 to 28, 2027 · next May 7
- 4 fees due Jun 8 to 29, 2027 · next Jun 8
- 2 fees due Jul 14 to 28, 2027 · next Jul 14
- 3 fees due Aug 23 to 27, 2027 · next Aug 23
- 3 fees due Sep 5 to 30, 2027 · next Sep 5
- 2 fees due Oct 12 to 23, 2027 · next Oct 12
Recent changes
- 1 term has ended since Aug 24, 2026
- Sep 20 US 11,446,300 Cerdulatinib for Treating Hematological Cancers · lapsed on the fee record
What they patent
The largest of its 101 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,000,133 | Antibodies to OX-2/CD200 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,718,880 | Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement In force · Medium confidence | In force | Medium confidence | |
| US 9,725,504 | Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement In force · Medium confidence | In force | Medium confidence | |
| US 9,732,149 | Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement In force · Medium confidence | In force | Medium confidence | |
| US 10,703,809 | Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement In force · Medium confidence | In force | Medium confidence | |
| US 8,709,415 | Antibodies to OX-2/CD200 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 7,851,505 | Thiotungstate Analogues and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,590,189 | Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement In force · Medium confidence | In force | Medium confidence | |
| US 8,075,884 | Antibodies to OX-2/CD200 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,096,677 | Humaneered Anti-Factor B Antibody In force · High confidence | In force | High confidence |
Also on record, not counted in the 168: 26 patents in force now held by others · 86 patents ended · 89 applications pending · 240 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.